
CAS 2040295-03-0
:PLX3397 HCl
- Pexidartinib hcl
- PLX3397 HCl
- Pexidartinib hydrochloride (PLX-3397)
- Pexidartinib Hydrochloride Salt
5-((5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine hydrochloride
CAS:5-((5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine hydrochloridePureza:99%Peso molecular:454.28g/molPexidartinib hydrochloride
CAS:Pexidartinib hydrochloride (PLX-3397 HCl) is a selective, orally active, ATP-competitive CSF1R/M-CSFR and c-Kit inhibitor with IC50 values of 20 and 10 nM.Fórmula:C20H16Cl2F3N5Pureza:99.88%Cor e Forma:SolidPeso molecular:454.28Pexidartinib Hydrochloride Salt
CAS:Produto ControladoApplications Pexidartinib Hydrochloride is RTK inhibitor. It can be used in pharmacological activity, therapeutic use, and biological study of inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
References Mok, S., et al.: BMC Cancer, 15, 1, 2015Fórmula:C20H15ClF3N5·ClHCor e Forma:NeatPeso molecular:454.276Pexidartinib hydrochloride
CAS:Pexidartinib hydrochloride is a potent, selective inhibitor of the receptor tyrosine kinases (RTKs) insulin-like growth factor 1 receptor (IGF1R) and c-Kit. It has been shown to inhibit the growth of cancer cells and myeloid leukemia cells. Pexidartinib hydrochloride has an excellent safety profile, with no serious adverse effects observed in clinical studies, and it is not associated with the development of drug resistance. The drug was well tolerated in patients with advanced solid tumors or myeloid malignancies who had failed prior treatment with other anticancer agents.
Fórmula:C20H16Cl2F3N5Pureza:Min. 95%Peso molecular:454.3 g/mol



